{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:57:17Z","timestamp":1791241037054,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104810","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:27:13Z","timestamp":1790206033000},"page":"104810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges and progress in access to rare cancer drugs in China: Insights from clinical trials, availability and affordability"],"prefix":"10.1016","volume":"31","author":[{"given":"Xingxian","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104810_b0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1470-2045(15)00485-4","article-title":"The promise and challenges of rare cancer research","volume":"17","author":"Komatsubara","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104810_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.drudis.2026.104810_b0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13023-022-02440-4","article-title":"Current status and trend of clinical development of orphan drugs in China","volume":"17","author":"Xiang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104810_b0020","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11427-023-2422-x","article-title":"Challenges and opportunities in rare cancer research in China","volume":"67","author":"Xue","year":"2024","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.drudis.2026.104810_b0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3654","article-title":"Rare diseases and orphan drugs","volume":"11","author":"Melnikova","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104810_b0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/d41573-023-00177-8","article-title":"Trends in rare disease drug development","volume":"23","author":"Chen","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104810_b0035","first-page":"93","article-title":"A glimpse into the future: mapping global research trends in immunotherapy for rare tumors","volume":"4","author":"Zhao","year":"2023","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.drudis.2026.104810_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13023-016-0392-4","article-title":"The availability and affordability of orphan drugs for rare diseases in China","volume":"11","author":"Gong","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104810_b0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5582\/irdr.2022.01093","article-title":"Incidence and prevalence of 121 rare diseases in China: current status and challenges: 2022 revision","volume":"11","author":"Lu","year":"2022","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.drudis.2026.104810_b0050","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13023-022-02507-2","article-title":"Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges","volume":"17","author":"Qiao","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104810_b0055","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(16)30418-4","article-title":"Challenges of rare diseases in China","volume":"387","author":"Dong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104810_b0060","first-page":"2027","article-title":"A review of China\u2019s rare disease drug policies and their implementation effectiveness","volume":"34","author":"Cui","year":"2025","journal-title":"Chin J New Drugs"},{"key":"10.1016\/j.drudis.2026.104810_b0065","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13023-023-02684-8","article-title":"Analysis of incentive policies and initiatives on orphan drug development in China: challenges, reforms and implications","volume":"18","author":"Zhao","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104810_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103370","article-title":"Assessment of the breakthrough-therapy-designated drugs granted in China: a pooled analysis 2020-2022","volume":"27","author":"Luo","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104810_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1223056","article-title":"Seven-year exclusivity and beyond for drugs of rare diseases in China","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104810_b0080","unstructured":"Center for Drug Evaluation. National medical products administration. pilot program on patient-centered drug development for rare diseases (CARE program). Center for Drug Evaluation Website. Published 2024. Accessed 7 September 2026. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/244dc3661a418359aa12d7cba9bacf5d."},{"key":"10.1016\/j.drudis.2026.104810_b0085","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(19)32179-8","article-title":"Orphan drug development in China: progress and challenges","volume":"394","author":"Zhang","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104810_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106349","article-title":"Clinical trials of orphan drugs in China over the decade 2012\u20132022: opportunities and challenges","volume":"182","author":"Wu","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104810_b0095","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104810_b0100","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jama.2023.3079","article-title":"Five-year sales for newly marketed prescription drugs with and without initial Orphan Drug Act designation","volume":"329","author":"Tu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104810_b0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1377\/hlthaff.2020.01442","article-title":"Spending for orphan indications among top-selling orphan drugs approved to treat common diseases","volume":"40","author":"Chua","year":"2021","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.drudis.2026.104810_b0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamainternmed.2023.6293","article-title":"Cost of exempting sole orphan drugs from Medicare negotiation","volume":"184","author":"Vogel","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.drudis.2026.104810_b0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cpt.2755","article-title":"Assessment of the delay in novel anticancer drugs between China and the United States: a comparative study of drugs approved between 2010 and 2021","volume":"113","author":"Luo","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104810_b0120","article-title":"The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis","volume":"32","author":"Luo","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.drudis.2026.104810_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102177","article-title":"Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022","volume":"63","author":"Luo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drudis.2026.104810_b0130","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S1470-2045(19)30491-7","article-title":"Changes in clinical trials of cancer drugs in mainland China over the decade 2009\u201318: a systematic review","volume":"20","author":"Li","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104810_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107488","article-title":"Trends of drug licensing in China: from bring-in to go-global","volume":"210","author":"Jiang","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104810_b0140","unstructured":"Center for Drug Evaluation. National medical products administration. Drug clinical trial registration and information publicity platform. Accessed 7 September 2026. https:\/\/www.chinadrugtrials.org.cn\/."},{"key":"10.1016\/j.drudis.2026.104810_b0145","unstructured":"INSIGHT Database. DXY. Accessed 7 September 2026. https:\/\/db.dxy.cn\/."},{"key":"10.1016\/j.drudis.2026.104810_b0150","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104810_b0155","unstructured":"National Bureau of Statistics of China. Statistical Communiqu\u00e9 of the People's Republic of China on the 2025 National Economic and Social Development. National Bureau of Statistics of China Website. Published 28 February 2026 Accessed 7 September 2026. https:\/\/www.stats.gov.cn\/english\/PressRelease\/202602\/t20260228_1962661.html."},{"key":"10.1016\/j.drudis.2026.104810_b0160","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-014-0170-0","article-title":"A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov","volume":"9","author":"Bell","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104810_b0165","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s43441-023-00572-8","article-title":"Analysis on the marketing trend and approval lag of imported orphan drugs from 2010 to 2021 in China","volume":"57","author":"Peng","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104810_b0170","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(24)00286-9","article-title":"Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis","volume":"25","author":"Jenei","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104810_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104462","article-title":"Addressing global regulatory challenges in rare disease drug development","volume":"30","author":"Costa","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104810_b0180","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29006","article-title":"Follow-on indications for orphan drugs related to the inflation reduction act","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2026.104810_b0185","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fonc.2020.00536","article-title":"Comprehensive genomic profiling of rare tumors: routes to targeted therapies","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104810_b0190","article-title":"Long way to go: progress of orphan drug accessibility in China from 2017 to 2022","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104810_b0195","doi-asserted-by":"crossref","DOI":"10.2196\/57353","article-title":"Patterns of the health and economic burden of 33 rare diseases in China: nationwide web-based study","volume":"10","author":"Yu","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.drudis.2026.104810_b0200","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2214-109X(24)00056-1","article-title":"The landscape for rare diseases in 2024","volume":"12","author":"Health","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.drudis.2026.104810_b0205","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/jama.2024.21396","article-title":"Meeting the unmet needs in rare cancer: advancing treatment options for retinoblastoma and beyond","volume":"332","author":"Li","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104810_b0210","unstructured":"National Healthcare Security Administration, Ministry of Human Resources and Social Security. Notice on promulgating the national drug list for basic medical insurance, maternity insurance and employment injury insurance and the commercial health insurance innovative drug list. Published 7 December 2025 Accessed 7 September 2026. https:\/\/www.nhsa.gov.cn\/art\/2025\/12\/7\/art_104_18970.html."},{"key":"10.1016\/j.drudis.2026.104810_b0215","unstructured":"National Health Commission of the People's Republic of China. Ministry of Industry and Information Technology, China National Intellectual Property Administration, National Healthcare Security Administration, National Medical Products Administration. Notice on the issuance of the fourth batch of the Encouraged Generic Drug List. National Health Commission Website. Published 4 January 2026 Accessed 7 September 2026. https:\/\/www.nhc.gov.cn\/yaozs\/c100098\/202601\/b646423a2bda4b37a142bb9c3a9e4ccd.shtml."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:32:50Z","timestamp":1791239570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002151"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104810","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and progress in access to rare cancer drugs in China: Insights from clinical trials, availability and affordability","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104810"}}